Although these findings are encouraging, the LHCGR-dependent molecular mechanism at the basis of PCOS pathogenesis remains poorly understood and the role of the receptor as a potential target for pharmacological approach to the disease is under-researched [99]. This evidence concerns the gene LHCGR and polycystic ovary syndrome.